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Abstract  
BACKGROUND: Colorectal cancer (CRC) is one of the most common cancers worldwide. 
Microsatellite instability (MSI) is detected in about 15% of all colorectal cancers. CRC with MSI has 
particular characteristics such as improved survival rates and better prognosis. They also have a 
distinct sensitivity to the action of chemotherapy. 
 
AIM: The aim of the study was to detect microsatellite instability in a cohort of colorectal cancer 
Egyptian patients using the immunohistochemical expression of mismatch repair proteins (MLH1, 
MSH2, MSH6 and PMS2).  
MATERIAL AND METHODS: Cases were divided into Microsatellite stable (MSS), Microsatellite 
unstable low (MSI-L) and Microsatellite unstable high (MSI-H). This Microsatellite stability status 
was correlated with different clinicopathological parameters. 
RESULTS: There was a statistically significant correlation between the age of cases, tumor site & 
grade and the microsatellite stability status. There was no statistically significant correlation 
between the gender of patients, tumor subtype, stage, mucoid change, necrosis, tumor borders, 
lymphocytic response, lymphovascular emboli and the microsatellite stability status.
 
CONCLUSION: Testing for MSI should be done for all colorectal cancer patients, especially those 
younger than 50 years old, right sided and high-grade CRCs.
 
 
 
 
Introduction 
 
Globally, more than one million people get 
colorectal cancer annually [1]. It is the second most 
common cause of cancer in women (after breast 
cancer) and the third most common in men (after lung 
and prostate cancers) [2]. 
In Egypt, there was a rapid increase in 
colorectal cancer incidence, where the occurrence 
was formerly low. Egypt reveals an unusually high 
rate of colorectal carcinoma under age 40, low 
prevalence of colorectal polyps in cancer patients 
and a predominant cancer site in the rectum [3]. 
Colorectal cancer is a heterogeneous 
disease,  and so far four main molecular pathways 
have been identified. These four pathways are the 
Chromosomal Instability (CIN) Pathway, CpG Island 
Methylator Phenotype (CIMP) pathway, Microsatellite 
Instability (MSI) pathway and the Serrated pathway 
[4]. 
MSI is a kind of genomic instability that 
arises when mutations occur in nucleotide repeat 
sequences throughout the genome. These repeat 
sequences are known as microsatellites, and the 
discrepancy that arises between these sequences in 
tumor and germline cells is known as microsatellite 
instability [5]. MSI arises from defects in the DNA 
mismatch repair (MMR) system which corrects any 
errors made by DNA polymerases during the 
replication of DNA [6]. 
Lynch Syndrome (LS), previously termed 
hereditary non-polyposis colorectal cancer, is an 
inherited condition of defective DNA MMR and 
predisposes people to a variety of cancers [7]. 
Colorectal cancer is the most common type of cancer 
associated with Lynch syndrome [8]. 
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LS is caused by autosomal dominant 
heterozygous germline mutations in one of the four 
key MMR genes — the mutL homologue 1 
(MLH1)(chromosome 3p21.3),mutS homologue 
2(MSH2)(chromosome 2p22–21), mutS homologue 6 
(MSH6)(chromosome 2p16) or postmeiotic 
segregation increased 2 (PMS2)(chromosome 7p22.2) 
genes [9]. 
The loss of function occurs due to a germline 
mutation in one allele of one of the DNA- MMR 
genes; however, inactivation of the second allele, 
which is mostly acquired, is needed for the 
development of cancers [10]. 
MSI sporadic CRCs were found to be caused 
primarily by somatically acquired hypermethylation of 
both alleles of the MLH1 promoter, with resultant 
loss of MLH1 protein expression, which was closely 
associated with the presence of the oncogenic 
BRAFV600E mutation [11]. 
The DNA-MMR enzymes work in pairs 
(dimers- MLH1/PMS2 and MSH2/MSH6), and 
formation of the complex is important for their 
stability. When a MLH1 function is lost, 
immunoreactivity for PMS2 disappears. The same 
happens with MSH6; when the MSH2 function is lost. 
However, when the PMS2 orMSH6 function is lost, 
MLH1 and MSH2 find other MMR partners and 
hence appear partially preserved on 
immunohistochemistry [12]. 
Testing tumors for MSI by 
immunohistochemistry for MMR proteins and/or by 
molecular-based methods is routinely performed for 
patients diagnosed with colorectal carcinoma, 
primarily to screen for Lynch syndrome. Up to 15% 
of all colorectal carcinomas demonstrate MSI, more 
frequently secondary to acquired methylation of 
MLH1 (sporadic cases) than caused by a germline 
mutation (Lynch syndrome) [5]. 
From a clinical point of view, MSI-high (MSI-
H) tumors as compared with microsatellite stable 
(MSS) ones, are diagnosed at a younger age, with 
a predominance in the right colon, frequently raised 
from sessile serrated adenoma and are diagnosed at 
an earlier stage [13]. 
Mucinous cells, signet-ring cells and poorly 
differentiated cells are uncommon histologic types and 
are commonly observed in cancers with MSI-H [14]. 
Patients with MSI-positive tumors tend to have a 
better prognosis and are less likely to be associated 
with distant metastasis [15, 16]. 
The aim of the study was to detect 
microsatellite instability in a cohort of colorectal 
cancer Egyptian patients using the 
immunohistochemical expression of mismatch repair 
proteins (MLH1, MSH2, MSH6 and PMS2). 
 
Material and Methods 
 
Fifty-two cases of colorectal cancer were 
retrieved from the pathology department, Ahmed 
Maher teaching hospital, Cairo, Egypt during the 
period from January 2012 to December 2015. 
Demographic and clinical data of the patients were 
collected from the hospital files. 
Five thick sections were cut from Formalin-
fixed paraffin embedded tissue blocks and stained 
with Hematoxylin and eosin for routine 
histopathological examination and determination of 
tumor type, grade, stage of the tumor and reporting 
co-findings such as; areas of tumor necrosis, 
presence or absence of lymphovascular invasion and 
lymphocytic response. Mucinous carcinoma was 
diagnosed if > 50% of the lesion was composed of 
mucin. Signet ring cell carcinoma was diagnosed if > 
50% of tumor cells showed prominent 
intracytoplasmic mucin. Otherwise gland forming 
tumors without specific morphology were diagnosed 
as adenocarcinoma, NOS. 
Immunohistochemical staining was performed 
using immunostainer (Shandon Sequenza) using the 
labeled streptavidin biotin method with the following 
reagents: Diva Decloaker, pretreatment antigen – 
retrieval, (Biocare Medical Catalog number: DV2004 
LX, MX), Hydrogen peroxide block (Lab Vision, USA, 
Catalog number: TA-060-HP), Ultravision large 
volume detection system (Lab Vision, USA, Catalog 
number: TP-060- HL) including Ultra V Block, 
Biotinylated goat anti -polyvalent plus (link) & 
Streptavidin peroxidase plus (label) and DAB plus 
substrate system (Lab Vision, USA, Catalog number: 
TA-060-HDX) including DAB plus chromogen & DAB 
plus substrate.  
The primary antibodies were PMS-2: a mouse 
polyclonal antibody (Biocare Medical Catalog number: 
PM 344 AA), MLH-1: a mouse monoclonal antibody 
(Biocare Medical Catalog number: PM 220 AA), 
MSH-6: a mouse monoclonal antibody (Biocare 
Medical Catalog number: PM 265 AA) and MSH-2: a 
mouse monoclonal antibody (Biocare Medical Catalog 
number: PM 219 AA). 
Non-neoplastic colonic mucosa, stromal cells, 
infiltrating lymphocytes or the centres of lymphoid 
follicles, were used as  positive internal controls. 
Sections of the same tissue were used following the 
same procedure, but the PBS was used instead of the 
primary antibody were used as  negative internal 
controls. 
Cases were categorised into positive 
(nuclear staining within tumor cells) and negative 
(complete absence of nuclear staining within tumor 
cells with concurrent internal positive controls) [17]. 
Then cases were interpreted as Microsatellite 
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stable (MSS) when all the four antibodies show 
positive nuclear staining of the tumor cells, as 
Microsatellite unstable low (MSI-L) when one 
antibody shows negative nuclear staining of the 
tumor cells (Fig. 1) and as Microsatellite unstable 
high (MSI-H) when two antibodies or more show 
negative nuclear staining of the tumor cells (Fig.       2) 
[18]. 
Statistical analyses were performed using 
Statistical Package for Social Science (SPSS 17.0 
for Windows; SPSS Inc, Chicago, IL, 2010). Chi-
Square test was used to examine the variable. P- 
value is significant when ≤ 0.05. 
 
 
Results 
 
The patients’ age ranged from 27 to 87 years 
with a mean age of 55.86 ± 13.11 years with a male: 
female ratio ~1:1. 82.7% of cases were 
adenocarcinomas, NOS, 9.6% were a  mucinous 
carcinoma, and 7.7% were signet ring cell carcinoma.  
Both MLH-1 and PMS-2 were positive in 
61.5% of cases, both were lost in 30.8%, and PMS-2 
loss without MLH-1 loss was seen in 7.7%. Both of 
MSH-2 and MSH-6 were positive in 94.2% of 
cases, while the loss of MSH-6 without MSH-2 loss 
was seen in 5.8%. Accordingly; 57.7% of cases were 
MSS, 11.5% were MSI-L, and 30.8% were MSI-H. 
A
 
B
 
C
 
D
 
Figure 1: Immunohistochemical staining pattern of an MSI-L 
colorectal carcinoma with intact staining of MLH1 (A), PMS2 (B) 
and MSH2 (C) and isolated loss of MSH6 (D) with positive 
internal control (Upper left of D) 
 
On the correlation of the stability status with 
the clinicopathological parameters, there was a 
statistically significant correlation between patients’ 
age and microsatellite stability status; older age (≥ 50 
years), was associated with MSS status while younger 
age (< 50 years), was associated with MSI-H status. 
Also, MSI-L status was seen only in older age (P 
value = 0.034). Also, there was a statistically 
significant correlation between tumor site and 
microsatellite stability status, where the left and 
transverse colon tumors tend to be MSS, while right 
colon tumors tend to be MSI-H (P-value = 0.014). 
A significant relationship was found between 
tumor grade and microsatellite stability status after 
adding the MSS to MSI-L cases; MSS and MSI-L 
tumors tend to be low grade, while MSI-H tumors tend 
to be high grade. (P value= 0.025). 
A
 
B
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Figure 2: Immunohistochemical staining pattern of an MSI-H 
colorectal carcinoma with loss of both MLH1 (A) & PMS2 (B) with 
positive internal control (Upper left of A, B) and intact staining of 
MSH2 (C) & MSH6 (D) 
 
An insignificant correlation between the 
microsatellite stability status and patients’ sex, tumor 
subtype, tumor borders, tumor necrosis, lymphocytic 
response, lymphovascular emboli, T stage or lymph 
node status was found (Table 1). 
Table 1: Descriptive Statistics of clinicopathological parameters 
and microsatellite stability status of CRC cases 
 
MSS 
n (%) 
MSI-L 
n (%) 
MSI-H 
n (%) 
Total n (%) P value 
Age                     < 50 
                             ≥ 50 
9 (17.3) 
21 (40.4) 
0 (0) 
6 (11.5) 
9 (17.3) 
7 (13.5) 
18 (34.6) 
34 (65.4) 
0.034 
Gender                Male 
                            Female 
16 (30.8) 
14 (26.9) 
2 (3.8) 
4 (7.7) 
9 (17.3) 
7 (13.5) 
27 (51.9) 
25 (48.1) 
0.614 
Tumor site            Lt colon  
                           Rt colon  
                                   Transverse 
22 (42.3) 
6 (11.5) 
2 (3.8) 
5 (9.6) 
1 (1.9) 
0 (0) 
5 (9.6) 
11 (21.2) 
0 (0) 
32 (61.5) 
18 (34.6) 
2 (3.8) 
0.014 
Tumor type           Adenocarcinoma. 
                             Mucinous ca 
                             Signet ring ca 
25 (48.1) 
3 (5.8) 
2 (3.8) 
6 (11.5) 
0 (0) 
0 (0) 
12 (23.1) 
2 (3.8) 
2 (3.8) 
43 (82.7) 
5 (9.6) 
4 (7.7) 
0.729 
Tumor grade          Low 
                              High 
29 (55.8) 
7 (13.5) 
8 (15.4) 
8 (15.4) 
37 (71.2) 
15 (28.8) 
0.025 
Mucoid change      Present 
                              Absent 
10 (19.2) 
20 (38.5) 
2 (3.8) 
4 (7.7) 
5 (9.6) 
11 (21.2) 
17 (32.7) 
35 (67.3) 
0.989 
Tumor necrosis      Present 
                              Absent 
13 (25) 
17 (32.7) 
2 (3.8) 
4 (7.7) 
8 (15.4) 
8 (15.4) 
23 (44.2) 
29 (55.8) 
0.773 
Tumor border         Infiltrative 
                              Pushing 
18 (34.6) 
12 (23.1) 
3 (5.8) 
3 (5.8) 
11 (21.2) 
5 (9.6) 
32 (61.5) 
20 (38.5) 
0.698 
Lymphocytic response 
                              Mild 
                              Moderate 
                              Marked 
 
20 (38.5) 
8 (15.4) 
2 (3.8) 
 
3 (5.8) 
3 (5.8) 
0 (0) 
 
11 (21.2) 
4 (7.7) 
1 (1.9) 
 
34 (65.4) 
15 (28.8) 
3 (5.8) 
0.789 
Vascular emboli     Present 
                              Absent 
17 (32.7) 
13 (25) 
2 (3.8) 
4 (7.7) 
7 (13.5) 
9 (17.3) 
26 (50) 
26 (50) 
0.484 
T stage                  T1+T2 
                              T3+T4 
2 (3.8) 
28 (53.8) 
1 (1.9) 
5 (9.6) 
3 (5.8) 
13 (25) 
6 (11.5) 
46 (88.5) 
0.434 
N stage                  N0 
                              N1 
                              N2 
10 (19.2) 
14 (26.9) 
6 (11.5) 
5 (9.6) 
0 (0) 
1 (1.9) 
8 (15.4) 
3 (5.8) 
5 (9.6) 
23 (44.2) 
17 (32.7) 
12 (23.1) 
0.078 
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Discussion 
Colorectal cancer is a common malignancy. It 
is the fourth most common cause of cancer death 
after lung, stomach and liver cancer [2]. It is not 
uncommon among Egyptian patients and rates are 
higher in patients under 40 years of age [19]. 
CRC shows a significant heterogeneity in 
both prognosis and response to therapy, even within 
the same pathological stage. This clinical 
heterogeneity may be in part linked to genetic 
alterations occurring during the pathogenesis [20]. 
MSI represents a molecular hallmark of Lynch 
syndrome. Nevertheless, the majority of cases with 
MSI are sporadic, more often due to an epigenetic 
inactivation of hMLH1 [21]. 
Concerning the microsatellite stability status 
of the cases in this study, a significant relation was 
found between the microsatellite stability status and 
patients’ age, where older age is associated MSS 
status, and the younger age is associated with MSI-H 
status. This result is the same as that of Huang et al. 
[22] andof Yuan et al. [17]. Also, Jenkins et al. [23] and 
Greenson et al. [24] found that age under 50 years is 
a strong predictor of MSI. 
Table 2: Summary of other studies findings regarding 
clinicopathological parameters related to MSI-H 
 Parameters related to MSI-H 
Faghani et al. [25] Left colon 
Frey et al. [26] Right colon and high grade 
Greenson et al. [24] Young age, right colon, high grade and mucinous differentiation 
Huang et al. [22] Young age, right colon, low grade and mucinous differentiation 
Jenkins et al. [23] Young age, right colon, high grade and mucinous differentiation 
Joel et al. [28] Low grade 
Raut et al. [13] High grade and mucinous differentiation 
Yearsley et al. [27] High grade and mucinous differentiation 
Yuan et al. [17] Young age 
 
On the contrary, Faghani et al. [25] found 
that there was no a statistically significant 
correlation between MSI and patients’ age, this can be 
explained by that their study was designed to 
determine the correlation between MSI and sporadic 
cases only. 
A significant relationship was found between 
the microsatellite stability status and tumor site where 
the left and transverse colon tumors tend to be MSS 
while right colon tumors tend to be MSI-H. Also, 
Huang et al. [22] and Frey et al. [26] found the 
same. Jenkins et al. [23] and Greenson et al. [24] 
found that right location was also a strong predictor of 
MSI. 
On the contrary, Faghani et al. [25] found that 
81.8% of total MSI-H had distal tumors. This is may 
be due to studyng only sporadic cases and analysis 
of MSI frequencies by testing the BAT-26 and BAT-25 
markers. 
Also, a significant relation was found between 
microsatellite stability status and the tumor grade, 
where MSS and MSI-L tumors tend to be low grade, 
while MSI-H tumors tend to be high grade. This is the 
same as Raut et al. [13], Yearsley et al. [27] and Frey 
et al. [26] results. Jenkins et al. [23] and Greenson 
et al. [24] found that poor or undifferentiated 
histology is a strong predictor of microsatellite 
instability. 
On the contrary, Joel et al. [28] found that the 
presence of well-differentiated tumors were important 
markers for microsatellite instability. Also, Huang et al. 
[22] found that MSI-H tumors were more likely to 
show less local aggressiveness and lower 
differentiation. These results may be due to the 
difference in the genetic and hereditary background 
among their patients and the Egyptian patients 
included in this study and use of molecular analyses 
besides the immunohistochemical tests. 
Although no significant relationship could be 
found in our study between the microsatellite stability 
status and tumor subtype or mucin presence, a great 
production of mucin with extracellular accumulation 
often correlates with MSI [29]. This discrepancy is 
due to the small number of mucinous and signet ring 
cell carcinoma cases in our study. Yearsley et al. [28] 
found the percentage of mucin differed significantly 
between MSI-H and MSI-L or MSS. Also, Raut et al. 
[13] and Huang et al. [22] found that MSI is 
associated with a mucinous histology. Jenkins et al. 
[23] and Greenson et al. [24] found that signet ring or 
focal signet ring differentiation and mucinous or focal 
mucinous differentiation were statistically significant 
predictors of microsatellite instability. 
In conclusion, our study showed a 
statistically significant correlation between patients’ 
age, tumor site and grade and the microsatellite 
stability status. It is recommended that testing for MSI 
is done for all colorectal cancer patients younger 
than 50 years old, right sided and high-grade 
tumors. Further studies on a larger number of patients 
should be done to study the relation between MSI and 
other pathological parameters. 
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